Evidence map›Paper›PMID 42199929›Full record

ArticleiScience2026

Density-adjusted analysis of cell interactions to decipher tissue landscape changes.

Misha Siddiqui, Azam Hamidinekoo, Jennifer Y Tan, Renata Leke, Bader Zarrouki, Nick Trahearn, Yeman Brhane Hagos, Chirine Sakr, Andrea Lampis, Christopher Bagnall and 6 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Misha SiddiquiMolecular Pathology, The Institute of Cancer Research (ICR), London, UK.
Azam HamidinekooImage Analysis and Platform, Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Jennifer Y TanImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Renata LekeBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Bader ZarroukiBioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Nick TrahearnEvolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Yeman Brhane HagosImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Chirine SakrEvolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Andrea LampisEvolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Christopher BagnallIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Giovanni PellegriniAptuit (Verona) Srl, an Evotec Company, Campus Levi Montalcini, Verona, Italy.
Simon P CastilloDepartment of Translational Molecular Pathology Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Benjamin ChallisTranslational Science & Experimental Medicine Research and Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Yinyin YuanDepartment of Translational Molecular Pathology Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marco BezziMolecular Pathology, The Institute of Cancer Research (ICR), London, UK.
Stephanie LingIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-cell proximity influences tissue homeostasis and disease progression, yet robust quantification across varying cell abundances remains challenging. We introduce a Monte Carlo simulation framework using the G-function as a spatial randomness reference to detect proximity differences between case groups independent of cell count. Three metrics, G-area, G-difference, and G-ratio, were evaluated for summarizing G-function outputs, alongside established approaches such as the Morisita-Horn Index and likelihood ratio. G-area most accurately captured group-level proximity changes. To demonstrate generalizability, we validated G-area in two external multiplex imaging datasets from colorectal and prostate cancer. This framework provides a cell-count-robust method for spatial analysis, enabling more reliable detection of microenvironmental changes across diseases and imaging platforms.

Indexed as

cancercell biologycomputational bioinformatics

Identifiers

PMID42199929
PMCPMC13200125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.